AstraZeneca
highlights multiple high potential and novel combinations to drive next wave of growth cardiovascular renal metabolism advancing next generation medicines established with key foundational medicines leveraging new mechanisms to expand existing focus pursuing novel combinations to target complex conditions and address of disease | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
November 2024
Slide
19 of 38
Related slides by other companies
Genelux
Investor Presentation
December 2023
phase anti tumor activity as leading into combination a | Genelux
RayzeBio
IPO
September 2023
phase trial in first line combination treatment of | RayzeBio
BioAtla
Investor Presentation
January 2024
cab phase dose titration ongoing | BioAtla
Fusion Pharmaceuticals
Investor Presentation
November 2023
unlocking the potential of in novel targets sey discovery | Fusion Pharmaceuticals
Other recent decks by AstraZeneca
See all presentations (31 decks)
Results
February 2025
Results
November 2024
Investor Event
September 2024
Results
February 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io